Revenue segments as reported by the company.

Life Sciences and Applied Markets Group

Diagnostics and Genomics Group

Agilent CrossLab Group

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Agilent Technologies

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Agilent Technologies posts strong Q1 earnings, eyes PFAS testing and CRISPR expansion

Agilent Technologies delivered robust Q1 results, raised full-year guidance, and remains confident in its growth drivers. Despite challenges in the genomics market and uncertainties ahead, the company is strategically positioned to capitalize on opportunities and drive continued success.

Agilent reports strong Q2 earnings but revises down second-half forecast

Agilent Technologies delivered strong Q2 results but revised down second-half forecasts due to economic uncertainties. The company remains focused on driving margin expansion, cost efficiencies, and customer service excellence. Challenges from macroeconomic factors and market dynamics are being addressed with a strategic outlook for long-term growth.

Agilent Technologies faces China revenue challenges but eyes growth opportunities

Agilent Technologies faces revenue challenges in China but sees growth opportunities in companion diagnostics and liquid biopsy markets. The company remains confident in its ability to drive earnings growth despite recent setbacks.

Agilent reports mixed Q4 results, eyes steady recovery in 2024

Agilent Technologies reported mixed Q4 results with revenue decline but exceeded EPS guidance. While facing challenges in China and certain segments, the company anticipates slow but steady recovery for FY 2024. Agilent is focusing on cost-saving measures, pricing trends, and investments in growth areas like genomics and environmental solutions.

Agilent reports Q1 revenue decline, eyes global growth opportunities

Agilent Technologies' Q1 performance showed revenue decline but with strengths in certain segments like ACG and consumables. Challenges include revenue declines in DGG and LSAG impacting margins. Opportunities lie in global growth prospects and potential market surprises.

Agilent Technologies faces revenue decline but eyes growth opportunities ahead

Agilent Technologies navigated a challenging market in Q2 2024 with revenue declines across all end markets. The company remains focused on customer-centric strategies, cost optimization, and growth investments while addressing visibility challenges and exploring opportunities in high-growth segments.

Agilent reports Q3 earnings beat, eyes growth through acquisitions

Agilent Technologies delivered a solid performance in Q3 2024, exceeding earnings per share guidance and raising revenue and EPS midpoint guidance.
While facing revenue decline, the company's strategic investments and acquisitions signal a focus on growth and innovation.
Challenges include market dynamics and integration risks, but opportunities exist in leveraging digital initiatives and financial strength for future growth.

Agilent Technologies reports robust Q4 performance and outlines growth strategies

Agilent Technologies' Q4 2024 earnings call highlighted strong financial performance, strategic acquisitions, and a focus on margin expansion for sustainable growth.
Despite regional challenges and market uncertainties, the company remains optimistic about future prospects and is committed to driving EPS growth.
With a new market-focused approach and ongoing transformation initiatives, Agilent is well-positioned to capitalize on opportunities and navigate potential challenges in FY 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that CEO Padraig McDonnell and CFO Bob McMahon will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, Jan. 14, 2025, at 9:45 a.m. Pacific time. A live audio webcast and replay of the presentation will be available on the Agilent Investor Relations website. About Agilent Technologies Agilent Technologies Inc. (NYSE: A) is a global leader in analytical and clinical lab.

Agilent to Present at the 43rd Annual J.P. Morgan Healthcare Conference

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the issuing of a Class C companion diagnostic In Vitro Diagnostic Regulation (IVDR) certification for PD-L1 IHC 28-8 pharmDx (Code SK005). This CDx assay has previously been CE-IVD–marked for sales in the European Union and is now certified in accordance with the new EU Regulation for in vitro diagnostic medical devices (IVDR) 1. PD-L1 IHC 28-8 pharmDx is approved for exclusive use with the Agilent Autosta.

Agilent Companion Diagnostic Assay PD-L1 IHC 28-8 pharmDx Receives European IVDR Certification

A's shares ride on the bright performance of the Agilent CrossLab Group segment and strategic acquisitions.

Agilent Gains 5% in a Month: Should You Buy, Sell or Hold the Stock?

Examine Agilent's (A) international revenue patterns and their implications on Wall Street's forecasts and the prospective trajectory of the stock.

International Markets and Agilent (A): A Deep Dive for Investors

A's fourth-quarter 2024 results benefit from strong demand in the ACG segment. However, declining sales in the Americas and China markets raise concerns.

Agilent Q4 Earnings Surpass Estimates, Revenues Increase Y/Y

I reiterate a “Buy” rating on Agilent Technologies, Inc. with a one-year target price of $150 per share, driven by strategic growth and market recovery. Agilent's acquisition of BIOVECTRA will enhance its CDMO business, focusing on oligonucleotides and CRISPR therapeutics, and expand service offerings in peptide synthesis. Agilent's FY25 guidance includes 2.5%-3.5% core revenue growth and 5.8% adjusted EPS growth, aligned with market expectations and supported by segment-specific growth strategies.

Agilent Q4: Expecting Market Recovery In 2025

Agilent Technologies, Inc. (NYSE:A ) Q4 2024 Results Conference Call November 25, 2024 4:30 PM ET Company Participants Parmeet Ahuja - Vice President, Investor Relations Padraig McDonnell - President and CEO Bob McMahon - Senior Vice President and CFO Simon May - President, Life Sciences and Diagnostic Markets Group Phil Binns - President, Life Sciences & Applied Markets Group Angelica Riemann - President, Agilent CrossLab Group Mike Zhang - President, Applied Markets Group Conference Call Participants Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Rachel Vatnsdal - JPMorgan Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Dan Leonard - UBS Puneet Souda - Leerink Partners Tycho Peterson - Jefferies Brandon Couillard - Wells Fargo Doug Schenkel - Wolfe Research Michael Ryskin - Bank of America Dan Brennan - TD Cowen Operator Good afternoon. My name is Rob, and I will be your conference operator today.

Agilent Technologies, Inc. (A) Q4 2024 Earnings Call Transcript

The headline numbers for Agilent (A) give insight into how the company performed in the quarter ended October 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Agilent (A) Reports Q4 Earnings: What Key Metrics Have to Say

Agilent Technologies (A) came out with quarterly earnings of $1.46 per share, beating the Zacks Consensus Estimate of $1.41 per share. This compares to earnings of $1.38 per share a year ago.

Agilent Technologies (A) Beats Q4 Earnings and Revenue Estimates

Agilent forecast its annual profit below analysts' estimates on Monday, as a recovery is ongoing in the market for medical tools and equipment used in clinical studies, sending its shares down more than 2% after the bell.

Medical equipment maker Agilent's downbeat annual forecast clouds fourth-quarter beat

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today reported revenue of $1.70 billion for the fourth quarter ended October 31, 2024, an increase of 0.8% reported and a decline of 0.3% core(1) compared to the fourth quarter of 2023. Fourth-quarter GAAP net income was $351 million, or $1.22 per share. This compares with $475 million, or $1.62 per share, in the fourth quarter of fiscal year 2023. Non-GAAP(2) net income was $418 million, or $1.46 per share during the qua.

Agilent Reports Fourth-Quarter Fiscal Year 2024 Financial Results

Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell on Monday, Nov. 25.

Agilent Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced a new organizational structure to accelerate the company's operational transformation to drive higher growth through a market-focused, customer-centric enterprise strategy. The new structure, including new leadership roles, takes effect immediately. “This is an important step in our transformation to become a nimbler company that puts our customers and our markets first,” said Agilent President and CEO Pad.

Agilent Announces New Organizational Structure to Support its Market-Focused Strategy

A's fourth-quarter performance is expected to have benefited from the growing ACG segment. However, falling end-market and regional sales raise concerns.

Agilent to Report Q4 Earnings: What's in the Cards for the Stock?

Agilent Technologies, Inc. A will release earnings results for the fourth quarter, after the closing bell, on Monday, Nov. 25.

How To Earn $500 A Month From Agilent Stock Ahead Of Q4 Earnings

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies, Inc. (NYSE: A) today announced the company has increased its quarterly dividend to 24.8 cents per share of common stock, a 5% increase over the previous dividend. The quarterly dividend will be paid on Jan. 22, 2025, to all shareholders of record as of the close of business on Dec. 31, 2024. The timing and amounts of future dividends are subject to determination and approval by Agilent's board of directors. About Agilent Technologies A.

Agilent Increases Cash Dividend to 24.8 Cents per Share

Agilent Technologies Inc (NYSE:A) is scheduled to release fourth-quarter financial results after the close on Monday, Nov. 25.

What to Expect from Agilent's Quarterly Report

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Agilent (A), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended October 2024.

Stay Ahead of the Game With Agilent (A) Q4 Earnings: Wall Street's Insights on Key Metrics

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announced today that Adeyemi Adeleye, Ph.D., has received the Agilent 2024 Early Career Professor Award for his contribution to environmental health and sustainability, developing green analytical technologies, methods, or laboratory working environments. Dr. Adeleye is an assistant professor in the Department of Earth and Environmental Engineering at Columbia University. The 2024 award focused on contributions to academi.

Agilent 2024 Early Career Professor Award Presented to Adeyemi Adeleye

CAMBRIDGE, England--(BUSINESS WIRE)--Tagomics Ltd., a pioneering biomarker discovery and diagnostics company, today announced it has entered into a strategic co-marketing agreement with Agilent Technologies, a leading tools provider in the genomics sector. The agreement offers select customers the opportunity to access Tagomics' and Agilent Technologies' combined innovative offerings through an exclusive technology access program hosted out of Tagomics' service lab in Cambridge. Tagomics has de.

Tagomics Announces a Multiomic Profiling Co-Marketing Agreement with Agilent

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the company has been named to Fortune's list of Best Workplaces in the World, ranking no. 11 among 25 companies. The list is based on 7.4 million responses to the Great Place to Work survey, which represents the experiences of 20 million employees worldwide. The survey assesses employee satisfaction in key areas, from credibility and respect to fairness and camaraderie. “Being named one of the best workpla.

Agilent Ranks No. 11 on Fortune's List of Best Workplaces in the World

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) announces the new Mito-rOCR Assay Kit. This easy and streamlined end-to-end solution makes sophisticated analysis of mitochondrial function available to researchers of all skill levels. With this cost-effective and versatile kit, researchers can easily incorporate functional assessment of relative mitochondrial respiration into their cell physiology and disease pathology studies. Mitochondria are central to energy product.

Agilent Announces the Innovative Mito-rOCR Assay Kit for Mitochondrial Research

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Professor Isabelle Plante at Institut National de la Recherche Scientifique (INRS), and Professor Bangyan Stiles at the University of Southern California (USC) are recipients of an Agilent Solutions Innovation Research Award (SIRA). The honorees will receive separate awards on behalf of their institutions in recognition of their research in cell and gene therapy. Developing new cell and gene therapies.

Agilent Presents Solutions Innovation Research Awards to Institut National de la Recherche Scientifique and University of Southern California Scientists

A's expanding LSAG portfolio may bode well for the stock, despite macroeconomic risks and stretched valuation.

Agilent Expands LSAG Segment: How Should You Approach the Stock?

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the release of its next generation Agilent InfinityLab LC Series portfolio, which includes the 1290 Infinity III LC, 1260 Infinity III Prime LC, and 1260 Infinity III LC systems, all including the biocompatible versions. These are the first HPLC systems on the market to feature the new Agilent InfinityLab Assist Technology, offering enhanced, built-in system assistance capabilities. This technology allows.

News for Agilent Technologies Stock (A)